Nabriva Therapeutics Ag

Nabriva Therapeutics Forschungs Gmbh

Ariva Med Gmbh

Klaus Thirring

Werner Heilmayer

Rosemarie Riedl

Susanne Paukner

Hermann Kollmann

Wolfgang Wicha

Gerd Ascher

Rodger Novak

Dirk B Strickmann

Zrinka Ivezic-Schoenfeld

Josef Wieser

Dirk Strickmann

A compound of compound according to formula (I): wherein X is selected from the group consisting of CH, CCl and N, Z is selected from the group consisting of CHCOOH, CH(CH)COOH, C(CH)COOH and CHF, D is a single bond connecting A and Ar or selected from the group consisting of CO, NHCO and N(C)alkyl-CO, A is selected from the group consisting of a (C)alkanediyl and a (C)cycloalkanediyl or, if D is N(C)alkyl-CO, A forms a 4- to 7-membered aliphatic heterocyclic ring with the nitrogen atom of N(C)alkyl-CO in D, and Ar is a 6-membered aromatic ring with a first hydroxyl group in para-position to D, a second hydroxyl group in meta-position to D, and with at least one electron-withdrawing element and uses thereof.

Siderophore cephalosporin conjugates and uses thereof

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

12-epi pleuromutilins

Compounds selected from the group of N-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C)alkyl-hydroxy-cycloalkyl- or bicycloalkylsulfanyl)-acetyl]-mutilins which are 14-O-[(amino(C)alkyl-hydroxy-cyclobutylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C)alkyl-hydroxy-cyclopentylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C)alkyl-hydroxy-cycloheptylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C)alkyl-hydroxy-cyclooctylsulfanyl)-acetyl]-mutilins, or 14-O-[(amino(C)alkyl-hydroxy-bicycloalkylsulfanyl)-acetyl]-mutilins, optionally in the form of a salt and/or a solvate, a pharmaceutical compositions comprising such compounds and their use as pharmaceuticals, e.g. for the treatment of microbial infections and for the treatment of acne, optionally in combination with other pharmaceutically active agents.

Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes

A compound of formula (I) wherein Y is oxygen or sulfur, and X, Xand Xare independently of each other hydrogen, halogen, hydroxy or linear or branched (C)-alkoxy, or hydroxy-(C)alkyl or (C)alkoxy-(C)alkyl, mono- or dihalogenated (C)-alkyl, amino(C)-alkyl, hydroxy(C)-alkyl, with one of the two provisos that: (1) at least of X, Xand Xis other than hydrogen, and (2) Xis other than hydroxy, when Xand Xare hydrogen. 

Organic compounds

A compound of formula (I) or of formula (II) wherein X is oxygen or sulfur, and Y is a residue of pipecolic acid or a residue of an amino acid, preferably a naturally occurring amino acid. 

Pleuromutilin derivatives and their use as antimicrobials

14-O&#x2014;[(((C)Alkoxy-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O&#x2014;[(((C)Mono- or dialkylamino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Hydroxy-(C)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Formyl-(C)-alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Guanidino-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Ureido-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Thioureido-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins, 14-O-[((Isothioureido-imino-(C)alkyl)-phenylsulfanyl)-acetyl]-mutilins and their use as pharmaceuticals.

Growing community of inventors

Vienna, Austria

Klaus Thirring